Jazz and PharmaMar’s Zepzelca Fails Phase 3 in Small Cell Lung Cancer
Strategic News Watch — June 12, 2026
Zepzelca failed its confirmatory phase 3 Lagoon trial in second-line small cell lung cancer, throwing Jazz and PharmaMar’s accelerated approval back into question — even as Britain cleared Novo Nordisk’s oral Wegovy and the FDA granted Roche priority review for adjuvant Tecentriq in colon cancer.
Today’s top developments:
- Jazz and PharmaMar’s Zepzelca missed its primary endpoint in the confirmatory phase 3 Lagoon trial for second-line small cell lung cancer (Fierce Pharma)
- The UK MHRA approved Novo Nordisk’s oral Wegovy, the first European green light for the semaglutide pill (pharmaphorum)
- The FDA granted priority review for Roche’s adjuvant Tecentriq combination in colon cancer (Pharmaceutical Technology)
- NICE recommended AbbVie’s atogepant for acute migraine in patients who haven’t responded to triptans (Pharmafile)
- Biotech IPO momentum continued with another record-breaking listing (Fierce Biotech)
What to Watch
- Zepzelca’s Regulatory Future — With the phase 3 Lagoon trial failure, Jazz and PharmaMar face potential withdrawal of accelerated approval and must decide whether to pursue alternative development strategies or exit the indication entirely.
- Biotech IPO Sustainability — Multiple record-breaking listings and substantial capital raises like Kardigan’s planned $350 million offering will test whether this market window represents durable investor appetite or a brief thaw before seasonal slowdown.
- Tecentriq Adjuvant Decision — Roche’s priority review decision expected within six months could validate immunotherapy’s role in early-stage colon cancer and establish a new standard of care in the adjuvant setting.
- Oral GLP-1 Access Race — Novo’s UK Wegovy pill approval pending NICE reimbursement, plus pending EU authorization, sets up a launch window where Novo can build oral share before Lilly’s Foundayo (orforglipron) scales up European availability — but tirzepatide (Zepbound) continues to erode Novo’s injectable position globally.
This brief highlights today’s top stories. Read the latest edition → for all stories, source links, and analysis.
